Skip to content

Peer-reviewed article

The FDA’s Dueling Narratives: Protector Versus Obstacle

The traditional narrative portrays the Food and Drug Administration as the protector of patients from drugs that have not been proven safe and effective. Recently, a different narrative has arisen that sees the agency as an obstacle to…

By John D. LantosJanuary 1, 20231 min readin Forefront Group

The traditional narrative portrays the Food and Drug Administration as the protector of patients from drugs that have not been proven safe and effective. Recently, a different narrative has arisen that sees the agency as an obstacle to patients and doctors who are capable of exercising their own judgments about safety and efficacy.

Originally published at Forefront Group · January 1, 2023.

About the author

John D. Lantos is a pediatrician and bioethicist writing on AI in medicine, neonatal intensive care, and end-of-life decisions. His essays appear in JAMA, JAMA Pediatrics, the Hastings Center Report, the New England Journal of Medicine, and Aeon. Read more about John.

The full archiveSubscribe